Introduction {#sec1}
============

Cancer-induced immune suppression prevents effective anti-tumor immune responses. Blockade of immune checkpoint molecules by monoclonal antibodies represents one form of immunotherapy to reverse this immune suppression in cancer patients. Antibodies targeting two such molecules, Programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4), have shown clinical benefit in several cancer types including metastatic melanoma.[@bib1], [@bib2] Adverse effects of these immune checkpoint inhibitors include immune-related adverse events (irAE), in which there is induction of new autoimmunity against tissues in the body. Dysfunction of endocrine glands are among the most common irAE, of which pituitary hypophysitis and autoimmune thyroiditis are likely the most common.[@bib3], [@bib4], [@bib5], [@bib6] Unique features of thyroiditis occurring during treatment with checkpoint inhibitor therapy have been recognized, including frequent lack of thyroperoxide (TPO) antibody that normally characterizes autoimmune thyroid disease.[@bib7] Despite increasing recognition of thyroiditis as a common adverse effect, there are no reports of the associated pathological findings that occur. Here, we present a case of immunotherapy-induced thyroiditis demonstrating unique cytopathologic features.

Case discussion {#sec2}
===============

A 51-year-old woman with metastatic melanoma was found to have a suppressed TSH and elevated free thyroxine concentration 14 days after starting treatment with nivolumab (PD-1 antagonist) plus ipilimumab (CTLA-4 antagonist) therapy. Of note, she had thyrotoxicosis with spontaneous resolution five years prior, but thyroid testing was normal at initiation of immunotherapy. An Iodine-123 uptake was 0.3% at 24 h and hypothyroidism subsequently developed requiring levothyroxine replacement, consistent with a thyroiditis. Restaging imaging showed a possible right thyroid nodule and ultrasound was obtained showing diffuse heterogeneity and hypervascularity, with a right 1.0 cm hypoechoic area. Fine needle aspiration biopsy was performed and cytopathology revealed a few lymphohistiocytic aggregates typical of Hashimoto thyroiditis ([Fig. 1](#fig1){ref-type="fig"}A), and a unique finding: abundant clusters of necrotic cells ([Fig. 1](#fig1){ref-type="fig"}B). Typical thyroid follicular cells were rare to absent. Immunostaining confirmed the presence of few AE1/AE3 keratin-positive thyroid follicular epithelial cells clustered with lymphocytes and CD163-positive histiocytes ([Fig. 1](#fig1){ref-type="fig"}C).Figure 1**Fine needle aspiration biopsy in thyroiditis induced by immune checkpoint therapy.** (A) Hematoxylin and eosin stained cell block, showing lymphohistiocytic aggregates (600×). (B) Papanicolaou stained ThinPrep showing necrotic cells with thyroid follicular cells rare to absent (600×). (C) Immunostain for CD163 (cell block) showing epithelial cells clustered with CD163^+^ histiocytes (600×).Fig. 1

The development of thyroiditis occurs commonly in patients treated with immune checkpoint therapy. Recognizing the pathologic features of this entity may help in understanding its mechanisms, which remain to be fully elucidated. In this case, cytopathology showed necrotic cells, together with lymphocytes and CD163^+^ histiocytes. CD163 is a hemoglobin scavenger receptor present on macrophages,[@bib8] typically of M2 phenotype involved in tissue repair. Such CD163^+^ macrophages have been observed in the tumor microenvironment of cancers and their abundance may increase after immune checkpoint therapy. While CD163^+^ cells may be found in patients with autoimmune thyroid disease, necrotic cells are not present in this context, making this a unique cytologic specimen. Our report is the first to show the possible cytologic findings indicative of thyroiditis associated with immune checkpoint therapy.
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